Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 17/20 | 0.71 |
| ▸ | CXCR1 | P25024 | 16/20 | 0.71 |
| ▸ | CCR6 | P51684 | 6/20 | 0.62 |
| ▸ | CCR7 | P32248 | 3/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.53 |
| ▸ | CCR4 | P51679 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24755300 | 0.92 | CCR6 (0.72) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL248399 | 0.84 | CXCR2 (0.69) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12087136 | 0.83 | CXCR2 (1.00) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL14894836 | 0.81 | CXCR1 (1.00) | CXCR2CXCR1CCR6CXCR3CCR4 | |
| SCHEMBL14894868 | 0.81 | CXCR1 (1.00) | CXCR2CXCR1CCR6CXCR3CCR4 | |
| SCHEMBL18310047 | 0.79 | CXCR2 (0.85) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL13344889 | 0.78 | CXCR2 (0.56) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL12263365 | 0.78 | CXCR2 (0.59) | CXCR2CXCR1CCR6CCR7CXCR3 | |
| SCHEMBL24755302 | 0.78 | CCR6 (0.73) | CXCR2CXCR1CCR6CCR7 | |
| SCHEMBL12087196 | 0.77 | CXCR2 (1.00) | CXCR2CXCR1CCR6CCR7CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.